Encorafenib + Binimetinib

DRUG7 trials

Conditions

Advanced Solid TumorBRAF V600 MutationCancerHepatic ImpairmentIn-Transit Metastasis of Cutaneous MelanomaMelanomaMelanoma BRAF V600E/K MutatedMelanoma Stage III

Phase 1

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

WithdrawnNCT04759846

Pierre Fabre MedicamentBRAF V600 Mutation, Hepatic Impairment, Metastatic Melanoma +1

Start: 2021-01-21End: 2023-05-31Updated: 2023-02-21

Phase 2

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active, not recruitingNCT03235245

European Organisation for Research and Treatment of Cancer - EORTCStage IV Melanoma, Unresectable Stage III Melanoma

Start: 2018-10-30End: 2027-01-31Updated: 2025-08-01

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

NCT05097378

CCTU- Cancer ThemeCancer, Melanoma

Start: 2022-01-01End: 2024-01-31Target: 45Updated: 2021-10-28

StrataPATH™ (Precision Indications for Approved Therapies)

TerminatedNCT05097599

Strata OncologyAdvanced Solid Tumor, Cancer

Start: 2022-04-29End: 2024-06-12Updated: 2025-01-08

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

NCT05767879

Leiden University Medical CenterIn-Transit Metastasis of Cutaneous Melanoma, Melanoma Stage III

Start: 2022-01-01End: 2026-01-01Target: 28Updated: 2023-03-14

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

RecruitingNCT06887088

Grupo Español Multidisciplinar de MelanomaMelanoma and Brain Metastases, Melanoma BRAF V600E/K Mutated

Start: 2025-05-29End: 2028-01-31Target: 33Updated: 2025-10-01

Unknown Phase

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

RecruitingNCT07022457

Pierre Fabre LtdMetastatic Melanoma, BRAF V600 Mutation Positive

Start: 2025-07-31End: 2028-01-13Target: 50Updated: 2025-08-03

Related Papers

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

2025-06-012 citations

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).

Journal of Clinical Oncology2024-06-108 citations

Abstract CT059: StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population

Cancer Research2023-04-14

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

Journal of Clinical Oncology2022-01-14151 citations